| Date Filed | Type | Description |
| 10/04/2023 |
SC 13D/A
| Morningside Venture Investments Ltd reports a 3.4% stake in Amylyx Pharmaceuticals, Inc. |
| 08/17/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/17/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/25/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/07/2023 |
SC 13D/A
| Morningside Venture Investments Ltd reports a 11.2% stake in GreenLight Biosciences Holdings, PBC |
| 04/03/2023 |
SC 13D/A
| Morningside Venture Investments Ltd reports a 12.9% stake in Amylyx Pharmaceuticals, Inc. |
| 02/23/2023 |
SC 13D/A
| Morningside Venture Investments Ltd reports a 30.2% stake in LumiraDx Limited |
| 02/14/2023 |
SC 13D
| Morningside Venture Investments Ltd reports a 30.2% stake in LumiraDx Limited |
| 12/02/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 09/30/2022 |
SC 13D/A
| Morningside Venture Investments Ltd reports a 15.9% stake in Amylyx Pharmaceuticals, Inc. |
| 02/16/2022 |
SC 13G/A
| Morningside Venture Investments Ltd reports a 0% stake in ATEA PHARMACEUTICALS, INC. |
| 02/14/2022 |
SC 13G
| Morningside Venture Investments Ltd reports a 40.9% stake in LUMIRADX LIMITED |
| 02/14/2022 |
SC 13D
| Morningside Venture Investments Ltd reports a 11.3% stake in GreenLight Biosciences Holdings, PBC |
| 02/14/2022 |
SC 13G/A
| Morningside Venture Investments Ltd reports a 13.2% stake in APELLIS PHARMACEUTICALS, INC. |
| 01/25/2022 |
SC 13D
| Morningside Venture Investments Ltd reports a 18.9% stake in Amylyx Pharmaceuticals, Inc. |
| 11/22/2021 |
SC 13D/A
| Morningside Venture Investments Ltd reports a 66.5% stake in Stealth BioTherapeutics Corp |
| 02/16/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/16/2020 |
SC 13D/A
| Morningside Venture Investments Ltd reports a 13.7% stake in Kezar Life Sciences, Inc. |
| 02/14/2020 |
SC 13D
| Morningside Venture Investments Ltd reports a 16% stake in Kezar Life Sciences, Inc. |
| 01/16/2020 |
SC 13G/A
| Morningside Venture Investments Ltd reports a 0% stake in NUCANA PLC |
| 05/24/2019 |
SC 13G/A
| Morningside Venture Investments Ltd reports a 19.3% stake in APELLIS PHARMACEUTICALS, INC. |
| 05/24/2019 |
SC 13G/A
| Morningside Venture Investments Ltd reports a 9% stake in NUCANA PLC |
| 05/24/2019 |
SC 13G/A
| Morningside Venture Investments Ltd reports a 12.1% stake in KEZAR LIFE SCIENCES, INC. |
| 03/22/2019 |
SC 13G/A
| Morningside Venture Investments Ltd reports a 19.3% stake in APELLIS PHARMACEUTICALS, INC. |
| 03/22/2019 |
SC 13G/A
| Morningside Venture Investments Ltd reports a 12.1% stake in KEZAR LIFE SCIENCES, INC. |
| 03/22/2019 |
SC 13G/A
| Morningside Venture Investments Ltd reports a 9% stake in NUCANA PLC |
| 03/13/2019 |
SC 13G/A
| Morningside Venture Investments Ltd reports a 19.3% stake in APELLIS PHARMACEUTICALS, INC. |
| 02/14/2019 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/14/2019 |
SC 13G
| Morningside Venture Investments Ltd reports a 12.1% stake in KEZAR LIFE SCIENCES, INC. |
| 02/14/2019 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/13/2018 |
SC 13G
| Morningside Venture Investments Ltd reports a 22.6% stake in APELLIS PHARMACEUTICALS, INC. |
| 02/13/2018 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |